Clinical and prognostic usefulness of soluble urokinase plasminogen activator receptor in hemodialysis patients

Wlazeł, Rafał Nikodem; Szadkowska, Iwona; Bartnicki, Piotr; Rośniak-Bąk, Kinga; Rysz, Jacek

doi:10.1007/s11255-017-1778-5

Cited by 17 publications

(18 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The present study excluded patients with CKD at stages greater than 3a. Nevertheless, suPAR level was found to strongly correlate with creatinine concentration and GFR across the studied group, which is in accordance with previous studies 2 – 4 , 18 , 19 . We are aware that the CKD-EPI formula was not standardized for the population of seniors 13 ; however, we used this formula, as currently recommended, to remain comparability with other studies concerning suPAR.…”

Section: Discussionsupporting

confidence: 92%

“…suPAR level was also found to strongly correlate with laboratory markers of kidney function. This observation is in accordance with the observation that in chronic kidney disease (CKD) the biomarker correlates with reduced GFR 18 , 19 . The present study excluded patients with CKD at stages greater than 3a.…”

Section: Discussionsupporting

confidence: 92%

“…A good correlation was also observed between suPAR and CRP in our patients and this relationship has also been frequently mentioned in previous studies 2 – 5 , 15 – 19 . Nevertheless, the p-values of our present findings were more robust for suPAR.…”

Section: Discussionsupporting

confidence: 91%

See 2 more Smart Citations

Soluble urokinase plasminogen activator receptor level in individuals of advanced age

Wlazeł

Szwabe

Guligowska

et al. 2020

Sci Rep

View full text Add to dashboard Cite

Soluble urokinase plasminogen activator receptor (suPAR) is a biomarker whose clinical value has been tested in various groups of patients. The aim of the present study was to determine the suPAR level in a previously uninvestigated population of 182, generally healthy, community-dwelling seniors aged 74–89 years. In addition to suPAR level, selected laboratory parameters of heart and kidney function, lipid and C-reactive protein levels were determined. A group of 45 younger individuals aged 24–66 years was used for comparison. The seniors had higher suPAR levels than younger controls: 3.79 ng/mL (95% CI 3.64–3.96 ng/mL) vs. 3.16 ng/mL (95% CI 2.86–3.45 ng/mL). These levels increased further with advancing age, and were similar in women and men. A multiple regression model confirmed that biomarker level was related to cardiac function, renal function and inflammation, and this remained after adjusting for age. These correlation patterns were similar in older women and men.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionsupporting

confidence: 92%

See 1 more Smart Citation

Soluble urokinase plasminogen activator receptor level in individuals of advanced age

Wlazeł

Szwabe

Guligowska

et al. 2020

Sci Rep

View full text Add to dashboard Cite

show abstract

“…In the pathogenesis of pFSGS, circulating factors have been regarded as significant because in about 40% of patients, this disease recurs after transplantation [2, 3]. The soluble urokinase plasminogen activator receptor (suPAR) is a protein circulating in the human blood and body fluids, which is present at low concentration in healthy individuals and high levels in patients with infections, chronic kidney disease (CKD), and other inflammatory disorders [4]. In that, its usefulness as a biomarker has been investigated in various diseases, such as sepsis [5], pneumonia [6], chronic obstructive pulmonary disease (COPD) [7], and kidney diseases including pFSGS [3, 8–10].…”

Section: Introductionmentioning

confidence: 99%

Increased Serum Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Levels in FSGS: A Meta-Analysis

Lee

Yang

Kronbichler

et al. 2019

Journal of Immunology Research

View full text Add to dashboard Cite

Introduction. The soluble urokinase-type plasminogen activator receptor (suPAR) has been found to be elevated in primary focal segmental glomerulosclerosis (pFSGS). However, its usefulness as a biomarker for FSGS remains controversial. We conducted a meta-analysis aiming at investigating the significance of suPAR in diagnosing pFSGS. Methods. Electronic databases (PubMed and EMBASE) were searched to identify studies comparing suPAR levels in FSGS patients and controls, from the earliest available date to May 1, 2018. A random-effects model with standardized mean difference (SMD) was used for meta-analyses. Risk of bias was assessed using the Newcastle-Ottawa quality assessment scale. Results. A total of 187 articles were screened, and the final analysis included 13 articles. In comparison to healthy controls, serum suPAR levels were significantly increased in pFSGS patients (SMD, 1.07, 95% confidence interval (CI) 0.65 to 1.48; participants=814; studies=9, I2=85%). Higher suPAR levels were also found in patients with pFSGS compared to those with minimal change disease (SMD 0.53, 95% CI 0.22 to 0.84). Of note, such a difference was not found in pediatric groups (SMD 0.42, 95% CI -0.13 to 0.96) while it was more evidently noted in adult patients (SMD 1.32, 95% CI 0.90 to 1.74). Serum suPAR levels did not differ between pFSGS patients in remission compared to those in active proteinuric state (SMD 0.29, 95% CI -0.30 to 0.88). Comparison with membranous nephropathy and IgA nephropathy showed no significant difference. Conclusions. Our meta-analysis demonstrated that, in comparison to both healthy controls and controls with minimal change disease, suPAR levels were significantly higher in adult patients with pFSGS. suPAR levels did not differ between pFSGS patients during the initial period of diagnosis and those in remission.

show abstract

“…Previous studies have shown that suPAR is associated with the coronary artery calcification (CAC) score (CACS) independently of the systematic coronary risk, and provides prognostic information on the CVD risk in the general population [4-7]. suPAR is also a biomarker strongly predictive of cardiovascular outcome in the pathogenesis of diabetic renal disease patients treated with hemodialysis [8-9]. However, it is unclear whether suPAR levels are associated with CAC in patients undergoing hemodialysis.…”

Section: Introductionmentioning

confidence: 99%

Soluble Urokinase Plasminogen Activator Receptor is Associated with Coronary Artery Calcification and Cardiovascular Disease in Patients Undergoing Hemodialysis

Cui

et al. 2018

Kidney Blood Press Res

View full text Add to dashboard Cite

Background/Aims: Cardiovascular disease (CVD) is an important cause of morbidity and mortality in hemodialysis patients. Vascular calcification is thought to play an important role in causing CVD. Soluble urokinase plasminogen activator receptor (suPAR) is a biomarker strongly predictive of cardiovascular outcomes in the pathogenesis of diabetic patients with renal disease treated with hemodialysis. We investigated the relationship between suPAR and coronary artery calcification (CAC) in patients undergoing maintenance hemodialysis. Methods: A total of 99 adult hemodialysis patients were enrolled in this study. Plasma samples were analyzed for suPAR with an enzyme-linked immunosorbent assay and the CAC score was determined with multidetector computed tomography. The occurrence of cardiovascular events and all-cause mortality during follow-up were recorded from January 1, 2010 to June 1, 2016. Results: In 99 patients treated with maintenance hemodialysis, 91 (91.9%) had varying degrees of CAC, and suPAR correlated positively with the CAC score in a Spearman analysis. In a mean follow-up period of 33 months, 36 patients (36.4%) experienced at least one cardiovascular event. When the quartiles of suPAR concentrations were used as the cutoff points for a subgroup analysis, the incidence of CVD and all-cause mortality was much higher in the higher quartiles of suPAR. In a univariate Cox regression analysis, high suPAR was a risk factor for CVD and all-cause mortality. Conclusion: suPAR is associated with the CAC score and is a risk factor for new-onset CVD in patients undergoing hemodialysis.

show abstract

Clinical and prognostic usefulness of soluble urokinase plasminogen activator receptor in hemodialysis patients

Cited by 17 publications

References 27 publications

Soluble urokinase plasminogen activator receptor level in individuals of advanced age

Soluble urokinase plasminogen activator receptor level in individuals of advanced age

Increased Serum Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Levels in FSGS: A Meta-Analysis

Soluble Urokinase Plasminogen Activator Receptor is Associated with Coronary Artery Calcification and Cardiovascular Disease in Patients Undergoing Hemodialysis

Contact Info

Product

Resources

About